We are very proud to announce our active participation in the next European Training Network ONCORNET 2.0. The ONCOgenic GPCR Network of Excellence and Training was funded with 4M EUR by the European Union. lnkd.in/eEmUFpw lnkd.in/er_bYMD

Great time at the BIO Convention in #Philly raising awareness about our #systemsbiology platform - better in-vitro to in-vivo translation! Thanks to Switzerland Global Enterprise SwissBiotech @_Innosuisse for your the support!

.InterAx assists biotech and pharma companies in intelligent drug candidate design & selection. Want to understand how their #systembiology platform works? Visit CEO Martin Ostermaier at the Swiss Pavilion (booth 3741) at the #BIO2019 convention. #biotech #innosuisse

#InterAx and #Boehringer Ingelheim engage in a collaboration #systemsbiology #drugdiscovery interaxbiotech.com/News_08.19-Boe…

We are very proud to announce that the #EU_EIC awarded InterAx with #horizon2020 SME Instrument Phase 2 for the integration of #machinelearning into the InterAx #systemsbiology platform for #drugdiscovery interaxbiotech.com/News_09.19-H20…

We are at the BioEurope! Rolf Rolli and Yaroslav Nikolaev are proudly representing InterAx in Hamburg this week. EBD Group #BIOEurope SwissBiotech #SwissPavilion, Hall B7, booth 158

InterAx Biotech AG and GPCR Therapeutics Inc. collaborate for the identification of compounds with superior biological properties targeting GPCR heteromers using the InterAx systems biology platform. lnkd.in/dDzKPgb #biotech #platform #systemsbiology #GPCR

#drugdiscovery #systemsbiology #artificial_intelligence #pharmacology2019

Absolutely fascinating talk on why AI and science need to now come together. Thanks to Danielle Ralic, CEO & Founder, IntrepidAnalytics. I have so many questions! #Pharmacology2019 #WomenInScience

Dr. Susanne Roth just gave an exciting talk about #drugdiscovery #systemsbiology #machinelearning #horizon2020 #EU_EIC at #Pharmacology2019 British Pharmacological Society

Happy to be one of the 10 Swiss Biotech Startups to watch in 2020! Thanks Venturelab to always keep a very close eye on the Swiss startup ecosystem, analyse trends and publish your reports. lnkd.in/dignhKt

InterAx and Prof. Jana Selent from the Hospital del Mar (IMIM) collaborates to identify antiviral drugs COVID-19 treatment by combining virtual screening of a 3D-structural database and assessing the effectiveness of these compounds to block viral entry. interaxbiotech.com/apr-2020/

Can we predict drug-GPCR #signaling and in vivo #pharmacology from drug#GPCRR structures? And thereby guide #DrugDesign? InterAx paves the way with a combination of #SystemsBiology and #MachineLearning / #AI. Supported by EU #H2020. Rec @CLINAM 2020 summit lnkd.in/dxS2hGx

Today InterAx is connecting with EIC Beneficiary colleagues, corporatesa and EIC staff memebrs at the #EUeic Innovation Hub Visit #EICAccelerator #H2020

European Research Network on Signal Transduction #ERNEST - Programme announced! Our CEO Aurélien Rizk is talking anout Integrating systems biology and #artificialitellegence to analyze and predict #GPCR signaling. April 12th, 14.00-14:30. Save the date! ernestcostaction.wixsite.com/website

If you want to learn about analysis of complex GPCR signaling data with #systemsbiology - see the talk of Susanne Roth at GM of the European Research Network on Signal Transduction #ERNEST. Today at 2-2:30 PM CET -> Register for free lnkd.in/diygMCp #Horizon2020 #EU_EIC

We are happy to announce that Prof. Dr. Ruedi Aebersold has joined the company Scientific Advisory Board (SAB) as a member. interaxbiotech.com/apr-2021/ #systemsbiology #artificialintelligence #drugdiscovery #gpcr #ethzurich #spinoff #PSI #eicaccelerator #h2020 #eufunding

InterA successfully completed its EU #H2020 project 4 months ahead of schedule. The newly developed discovery platform combines for the first time classical pharmacology, computational methods, systems biology and AI to revolutionise 💊 drug discovery. lnkd.in/dnH2Q9JK

InterAx is pleased to announce that Carola Weiss has joined the company as VP Business Development. Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical industry.

InterAx and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery platform. Collaborative efforts aim to accelerate and improve the prediction of first in class small molecule agonists for a challenging orphan GPCR 💊